Europe
The approval marks the first time the FDA has approved a checkpoint inhibitor for the treatment of advanced renal cell cancer.
A bacteriophage is a virus that infects bacteria. They aren’t typically used to treat bacterial infections, but in desperate cases, they have been used to treat particularly antibiotic-resistant infections.
DCprime today announced presentations of additional preclinical data sets for its lead program, DCP-001, at the 7th CCBIO Annual Symposium and the 2019 CIMT Annual Meeting.
Evotec SE reported financial results and corporate updates for the first quarter of 2019.
InflaRx today announced the treatment of the first patient in IXchange, a Phase II study with IFX-1 in patients with ANCA-associated vasculitis (AAV) (NCT03895801).
Data Safety Monitoring Board (DSMB) recommends the continuation of the RESOLVE-IT clinical trial without any modifications, based on the pre-planned review of safety data
Expedeon AG today announced that CEO Dr Heikki Lanckriet will deliver a presentation on 15 May 2019 at the German Spring Conference in Frankfurt.
Conference call and webcast (in English) today, May 14, 2019 at 3:00 pm CET / 9:00 am EST
Under the terms of the deal, AbbVie will grant Germany-based Boehringer Ingelheim a non-exclusive license for Cyltezo, its biosimilar to Humira.
The trial showed that the company’s auto-injector administered treatment delivered the same results as a previous trial using a pre-filled syringe.
PRESS RELEASES